Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Atossa Genetics Inc (NASDAQ:ATOS)

1.02
Delayed Data
As of Aug 03
 0.00 / 0.00%
Today’s Change
0.80
Today|||52-Week Range
2.65
-28.67%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$27.8M

Company Description

Atossa Genetics, Inc. is a healthcare company that is focused on the prevention of breast cancer through the commercialization of diagnostic tests that can detect precursors to breast cancer and through the research, development and ultimate commercialization of treatments for pre-cancerous lesions. It offers two diagnostic tests: ForeCYTE and ArgusCYTE. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test provides information to help inform breast cancer treatment options and to help monitor potential recurrence. The company also intends to offer two additional diagnostics tests: FullCYTE and NextCYTE. The FullCYTE Breast Health Test is designed to assess the individual breast ducts for pre-cancerous changes in women previously identified to be at high risk for breast cancer. The NextCYTE Breast Cancer Test is designed to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. Atossa Genetics was founded by Steven C. Quay in December 2008 and is headquartered in Seattle, WA.

Contact Information

Atossa Genetics, Inc.
1616 Eastlake Avenue East
Seattle Washington 98102
P:(206) 588-0256
Investor Relations:

Employees

Shareholders

Mutual fund holders2.35%
Individual stakeholders17.05%
Other institutional0.34%

Top Executives

Steven C. QuayChairman, President & Chief Executive Officer
Scott YoumansSenior Vice President-Operations
Kyle GuseCFO, Secretary & General Counsel
Michael H. KalnoskiMedical Director
Jelle W. KylstraVice President-Clinical Research & Development